APO Research
Talk to an analyst

APO RESEARCH · REPORT

Opioid-Induced Constipation

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Selected research

Industry Growth & Trends

Global Opioid-Induced Constipation Industry Growth and Trends Forecast to 2032

21 December 2025102 pages

Choose your research edition.

Industry ResearchOpioid-Induced Constipation Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioid-Induced Constipation Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Opioid-Induced Constipation Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioid-Induced Constipation Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioid-Induced Constipation Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.

North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.

Read the full market overview

In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.

Report Scope

This report provides a structured, data-driven view of the global Opioid-Induced Constipation market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Opioid-Induced Constipation market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Opioid-Induced Constipation market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Opioid-Induced Constipation.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Opioid-Induced Constipation market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Opioid-Induced Constipation Market by Company

Takeda Pharmaceuticals

Bayer

Sanofi

Mallinckrodt

Salix (Bausch Health)

AstraZeneca

Progenics Pharmaceuticals

Purdue Pharm

Nektar Therapeutics

Daiichi Sankyo

Prestige

GSK

Shionogi

Opioid-Induced Constipation Segment by Type

Methylnaltrexone Bromide

Lubiprostone

Naloxegol

Others

Opioid-Induced Constipation Segment by Application

Hospital

Pharmacy

Other

Opioid-Induced Constipation Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid-Induced Constipation market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioid-Induced Constipation and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid-Induced Constipation.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Opioid-Induced Constipation manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Opioid-Induced Constipation in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Methylnaltrexone Bromide Table 2. Major Company of Lubiprostone Table 3. Major Company of Naloxegol Table 4. Major Company of Others Table 5. Global Opioid-Induced Constipation Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Opioid-Induced Constipation Sales by Type (2021-2026) & (K Units) Table 7. Global Opioid-Induced Constipation Sales Market Share in Volume by Type (2021-2026) Table 8. Global Opioid-Induced Constipation Sales by Type (2021-2026) & (US$ Million) Table 9. Global Opioid-Induced Constipation Sales Market Share in Value by Type (2021-2026) Table 10. Global Opioid-Induced Constipation Price by Type (2021-2026) & (USD/Unit) Table 11. Global Opioid-Induced Constipation Sales by Type (2027-2032) & (K Units) Table 12. Global Opioid-Induced Constipation Sales Market Share in Volume by Type (2027-2032) Table 13. Global Opioid-Induced Constipation Sales by Type (2027-2032) & (US$ Million) Table 14. Global Opioid-Induced Constipation Sales Market Share in Value by Type (2027-2032) Table 15. Global Opioid-Induced Constipation Price by Type (2027-2032) & (USD/Unit) Table 16. North America Opioid-Induced Constipation Sales by Type (2021-2026) & (K Units) Table 17. North America Opioid-Induced Constipation Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Opioid-Induced Constipation Sales by Type (2021-2026) & (K Units) Table 19. Europe Opioid-Induced Constipation Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Opioid-Induced Constipation Sales by Type (2021-2026) & (K Units) Table 21. Asia-Pacific Opioid-Induced Constipation Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Opioid-Induced Constipation Sales by Type (2021-2026) & (K Units) Table 23. Latin America Opioid-Induced Constipation Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Opioid-Induced Constipation Sales by Type (2021-2026) & (K Units) Table 25. Middle East and Africa Opioid-Induced Constipation Sales by Type (2021-2026) & (US$ Million) Table 26. Opioid-Induced Constipation Industry Trends Table 27. Opioid-Induced Constipation Industry Drivers Table 28. Opioid-Induced Constipation Industry Opportunities and Challenges Table 29. Opioid-Induced Constipation Industry Restraints Table 30. Global Opioid-Induced Constipation Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Opioid-Induced Constipation Revenue Market Share by Company (2021-2026) Table 32. Global Opioid-Induced Constipation Sales by Company (2021-2026) & (K Units) Table 33. Global Opioid-Induced Constipation Sales Share by Company (2021-2026) Table 34. Global Opioid-Induced Constipation Market Price by Company (2021-2026) & (USD/Unit) Table 35. Global Opioid-Induced Constipation Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Opioid-Induced Constipation Major Company Production Sites and Headquarters Table 37. Global Opioid-Induced Constipation Company, Product Type & Application Table 38. Global Opioid-Induced Constipation Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Opioid-Induced Constipation by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Opioid-Induced Constipation Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Opioid-Induced Constipation Sales by Region (2021-2026) & (K Units) Table 43. Global Opioid-Induced Constipation Sales Market Share in Volume by Region (2021-2026) Table 44. Global Opioid-Induced Constipation Sales by Region (2021-2026) & (US$ Million) Table 45. Global Opioid-Induced Constipation Sales Market Share in Value by Region (2021-2026) Table 46. Global Opioid-Induced Constipation Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 47. Global Opioid-Induced Constipation Sales by Region (2027-2032) & (K Units) Table 48. Global Opioid-Induced Constipation Sales Market Share in Volume by Region (2027-2032) Table 49. Global Opioid-Induced Constipation Sales by Region (2027-2032) & (US$ Million) Table 50. Global Opioid-Induced Constipation Sales Market Share in Value by Region (2027-2032) Table 51. Global Opioid-Induced Constipation Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2027-2032) Table 52. Global Opioid-Induced Constipation Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Opioid-Induced Constipation Sales by Application (2021-2026) & (K Units) Table 54. Global Opioid-Induced Constipation Sales Market Share in Volume by Application (2021-2026) Table 55. Global Opioid-Induced Constipation Sales by Application (2021-2026) & (US$ Million) Table 56. Global Opioid-Induced Constipation Sales Market Share in Value by Application (2021-2026) Table 57. Global Opioid-Induced Constipation Price by Application (2021-2026) & (USD/Unit) Table 58. Global Opioid-Induced Constipation Sales by Application (2027-2032) & (K Units) Table 59. Global Opioid-Induced Constipation Sales Market Share in Volume by Application (2027-2032) Table 60. Global Opioid-Induced Constipation Sales by Application (2027-2032) & (US$ Million) Table 61. Global Opioid-Induced Constipation Sales Market Share in Value by Application (2027-2032) Table 62. Global Opioid-Induced Constipation Price by Application (2027-2032) & (USD/Unit) Table 63. North America Opioid-Induced Constipation Sales by Application (2021-2026) & (K Units) Table 64. North America Opioid-Induced Constipation Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Opioid-Induced Constipation Sales by Application (2021-2026) & (K Units) Table 66. Europe Opioid-Induced Constipation Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Opioid-Induced Constipation Sales by Application (2021-2026) & (K Units) Table 68. Asia-Pacific Opioid-Induced Constipation Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Opioid-Induced Constipation Sales by Application (2021-2026) & (K Units) Table 70. Latin America Opioid-Induced Constipation Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Opioid-Induced Constipation Sales by Application (2021-2026) & (K Units) Table 72. Middle East and Africa Opioid-Induced Constipation Sales by Application (2021-2026) & (US$ Million) Table 73. Takeda Pharmaceuticals Company Information Table 74. Takeda Pharmaceuticals Business Overview Table 75. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 76. Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolio Table 77. Takeda Pharmaceuticals Recent Development Table 78. Bayer Company Information Table 79. Bayer Business Overview Table 80. Bayer Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 81. Bayer Opioid-Induced Constipation Product Portfolio Table 82. Bayer Recent Development Table 83. Sanofi Company Information Table 84. Sanofi Business Overview Table 85. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 86. Sanofi Opioid-Induced Constipation Product Portfolio Table 87. Sanofi Recent Development Table 88. Mallinckrodt Company Information Table 89. Mallinckrodt Business Overview Table 90. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 91. Mallinckrodt Opioid-Induced Constipation Product Portfolio Table 92. Mallinckrodt Recent Development Table 93. Salix (Bausch Health) Company Information Table 94. Salix (Bausch Health) Business Overview Table 95. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 96. Salix (Bausch Health) Opioid-Induced Constipation Product Portfolio Table 97. Salix (Bausch Health) Recent Development Table 98. AstraZeneca Company Information Table 99. AstraZeneca Business Overview Table 100. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 101. AstraZeneca Opioid-Induced Constipation Product Portfolio Table 102. AstraZeneca Recent Development Table 103. Progenics Pharmaceuticals Company Information Table 104. Progenics Pharmaceuticals Business Overview Table 105. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 106. Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolio Table 107. Progenics Pharmaceuticals Recent Development Table 108. Purdue Pharm Company Information Table 109. Purdue Pharm Business Overview Table 110. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 111. Purdue Pharm Opioid-Induced Constipation Product Portfolio Table 112. Purdue Pharm Recent Development Table 113. Nektar Therapeutics Company Information Table 114. Nektar Therapeutics Business Overview Table 115. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 116. Nektar Therapeutics Opioid-Induced Constipation Product Portfolio Table 117. Nektar Therapeutics Recent Development Table 118. Daiichi Sankyo Company Information Table 119. Daiichi Sankyo Business Overview Table 120. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 121. Daiichi Sankyo Opioid-Induced Constipation Product Portfolio Table 122. Daiichi Sankyo Recent Development Table 123. Prestige Company Information Table 124. Prestige Business Overview Table 125. Prestige Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 126. Prestige Opioid-Induced Constipation Product Portfolio Table 127. Prestige Recent Development Table 128. GSK Company Information Table 129. GSK Business Overview Table 130. GSK Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 131. GSK Opioid-Induced Constipation Product Portfolio Table 132. GSK Recent Development Table 133. Shionogi Company Information Table 134. Shionogi Business Overview Table 135. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 136. Shionogi Opioid-Induced Constipation Product Portfolio Table 137. Shionogi Recent Development Table 138. North America Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 139. North America Opioid-Induced Constipation Sales by Country (2021-2026) & (K Units) Table 140. North America Opioid-Induced Constipation Sales Market Share by Country (2021-2026) Table 141. North America Opioid-Induced Constipation Sales Forecast by Country (2027-2032) & (K Units) Table 142. North America Opioid-Induced Constipation Sales Market Share Forecast by Country (2027-2032) Table 143. North America Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. North America Opioid-Induced Constipation Market Size by Country (2021-2026) & (US$ Million) Table 145. North America Opioid-Induced Constipation Market Share by Country (2021-2026) Table 146. North America Opioid-Induced Constipation Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. North America Opioid-Induced Constipation Market Share Forecast by Country (2027-2032) Table 148. Europe Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 149. Europe Opioid-Induced Constipation Sales by Country (2021-2026) & (K Units) Table 150. Europe Opioid-Induced Constipation Sales Market Share by Country (2021-2026) Table 151. Europe Opioid-Induced Constipation Sales Forecast by Country (2027-2032) & (K Units) Table 152. Europe Opioid-Induced Constipation Sales Market Share Forecast by Country (2027-2032) Table 153. Europe Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Europe Opioid-Induced Constipation Market Size by Country (2021-2026) & (US$ Million) Table 155. Europe Opioid-Induced Constipation Market Share by Country (2021-2026) Table 156. Europe Opioid-Induced Constipation Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Europe Opioid-Induced Constipation Market Share Forecast by Country (2027-2032) Table 158. Asia-Pacific Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 159. Asia-Pacific Opioid-Induced Constipation Sales by Country (2021-2026) & (K Units) Table 160. Asia-Pacific Opioid-Induced Constipation Sales Market Share by Country (2021-2026) Table 161. Asia-Pacific Opioid-Induced Constipation Sales Forecast by Country (2027-2032) & (K Units) Table 162. Asia-Pacific Opioid-Induced Constipation Sales Market Share Forecast by Country (2027-2032) Table 163. Asia-Pacific Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Asia-Pacific Opioid-Induced Constipation Market Size by Country (2021-2026) & (US$ Million) Table 165. Asia-Pacific Opioid-Induced Constipation Market Share by Country (2021-2026) Table 166. Asia-Pacific Opioid-Induced Constipation Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Asia-Pacific Opioid-Induced Constipation Market Share Forecast by Country (2027-2032) Table 168. Latin America Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 169. Latin America Opioid-Induced Constipation Sales by Country (2021-2026) & (K Units) Table 170. Latin America Opioid-Induced Constipation Sales Market Share by Country (2021-2026) Table 171. Latin America Opioid-Induced Constipation Sales Forecast by Country (2027-2032) & (K Units) Table 172. Latin America Opioid-Induced Constipation Sales Market Share Forecast by Country (2027-2032) Table 173. Latin America Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. Latin America Opioid-Induced Constipation Market Size by Country (2021-2026) & (US$ Million) Table 175. Latin America Opioid-Induced Constipation Market Share by Country (2021-2026) Table 176. Latin America Opioid-Induced Constipation Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. Latin America Opioid-Induced Constipation Market Share Forecast by Country (2027-2032) Table 178. Middle East and Africa Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 179. Middle East and Africa Opioid-Induced Constipation Sales by Country (2021-2026) & (K Units) Table 180. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Country (2021-2026) Table 181. Middle East and Africa Opioid-Induced Constipation Sales Forecast by Country (2027-2032) & (K Units) Table 182. Middle East and Africa Opioid-Induced Constipation Sales Market Share Forecast by Country (2027-2032) Table 183. Middle East and Africa Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 184. Middle East and Africa Opioid-Induced Constipation Market Size by Country (2021-2026) & (US$ Million) Table 185. Middle East and Africa Opioid-Induced Constipation Market Share by Country (2021-2026) Table 186. Middle East and Africa Opioid-Induced Constipation Market Size Forecast by Country (2027-2032) & (US$ Million) Table 187. Middle East and Africa Opioid-Induced Constipation Market Share Forecast by Country (2027-2032) Table 188. Key Raw Materials Table 189. Raw Materials Key Suppliers Table 190. Opioid-Induced Constipation Distributors List Table 191. Opioid-Induced Constipation Customers List Table 192. Research Programs/Design for This Report Table 193. Authors List of This Report Table 194. Secondary Sources Table 195. Primary Sources List of Figures Figure 1. Opioid-Induced Constipation Image Figure 2. Global Opioid-Induced Constipation Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Opioid-Induced Constipation Market Size (2021-2032) & (US$ Million) Figure 4. Global Opioid-Induced Constipation Sales (2021-2032) & (K Units) Figure 5. Methylnaltrexone Bromide Image Figure 6. Global Methylnaltrexone Bromide Sales YoY Growth (2021-2032) & (K Units) Figure 7. Lubiprostone Image Figure 8. Global Lubiprostone Sales YoY Growth (2021-2032) & (K Units) Figure 9. Naloxegol Image Figure 10. Global Naloxegol Sales YoY Growth (2021-2032) & (K Units) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 13. Global Opioid-Induced Constipation Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Opioid-Induced Constipation Market Share by Type 2025 VS 2032 Figure 15. North America Opioid-Induced Constipation Sales Market Share in Volume by Type in 2025 Figure 16. North America Opioid-Induced Constipation Sales Market Share in Value by Type in 2025 Figure 17. Europe Opioid-Induced Constipation Sales Market Share in Volume by Type in 2025 Figure 18. Europe Opioid-Induced Constipation Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Opioid-Induced Constipation Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Opioid-Induced Constipation Sales Market Share in Value by Type in 2025 Figure 21. Latin America Opioid-Induced Constipation Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Opioid-Induced Constipation Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Opioid-Induced Constipation Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Opioid-Induced Constipation Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Opioid-Induced Constipation Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospital Image Figure 28. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 29. Pharmacy Image Figure 30. Global Pharmacy Sales YoY Growth (2021-2032) & (K Units) Figure 31. Other Image Figure 32. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global Opioid-Induced Constipation Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Opioid-Induced Constipation Market Share by Application 2025 VS 2032 Figure 35. North America Opioid-Induced Constipation Sales Market Share in Volume by Application in 2025 Figure 36. North America Opioid-Induced Constipation Sales Market Share in Value by Application in 2025 Figure 37. Europe Opioid-Induced Constipation Sales Market Share in Volume by Application in 2025 Figure 38. Europe Opioid-Induced Constipation Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Opioid-Induced Constipation Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Opioid-Induced Constipation Sales Market Share in Value by Application in 2025 Figure 41. Latin America Opioid-Induced Constipation Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Opioid-Induced Constipation Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Opioid-Induced Constipation Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Opioid-Induced Constipation Sales Market Share in Value by Application in 2025 Figure 45. North America Opioid-Induced Constipation Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America Opioid-Induced Constipation Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Opioid-Induced Constipation Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Opioid-Induced Constipation Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Opioid-Induced Constipation Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe Opioid-Induced Constipation Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Opioid-Induced Constipation Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Opioid-Induced Constipation Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Opioid-Induced Constipation Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific Opioid-Induced Constipation Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Opioid-Induced Constipation Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Opioid-Induced Constipation Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Opioid-Induced Constipation Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America Opioid-Induced Constipation Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Opioid-Induced Constipation Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Opioid-Induced Constipation Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Opioid-Induced Constipation Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa Opioid-Induced Constipation Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Opioid-Induced Constipation Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Opioid-Induced Constipation Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Opioid-Induced Constipation Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Opioid-Induced Constipation Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Methylnaltrexone Bromide
  • Lubiprostone
  • Naloxegol
  • Others
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Takeda Pharmaceuticals
  • Bayer
  • Sanofi
  • Mallinckrodt
  • Salix (Bausch Health)
  • AstraZeneca
  • Progenics Pharmaceuticals
  • Purdue Pharm
  • Nektar Therapeutics
  • Daiichi Sankyo
  • Prestige
  • GSK
  • Shionogi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Opioid-Induced Constipation Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Opioid-Induced Constipation Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Opioid-Induced Constipation Market by Type
  6. 1.3.1 Methylnaltrexone Bromide
  7. 1.3.2 Lubiprostone
  8. 1.3.3 Naloxegol
  9. 1.3.4 Others
  10. 1.4 Global Opioid-Induced Constipation Market Size by Type
  11. 1.4.1 Global Opioid-Induced Constipation Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Opioid-Induced Constipation Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Opioid-Induced Constipation Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Opioid-Induced Constipation Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Opioid-Induced Constipation Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Opioid-Induced Constipation Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Opioid-Induced Constipation Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Opioid-Induced Constipation Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Opioid-Induced Constipation Industry Trends
  2. 2.2 Opioid-Induced Constipation Industry Drivers
  3. 2.3 Opioid-Induced Constipation Industry Opportunities and Challenges
  4. 2.4 Opioid-Induced Constipation Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Opioid-Induced Constipation Revenue (2021-2026)
  2. 3.2 Global Top Players by Opioid-Induced Constipation Sales (2021-2026)
  3. 3.3 Global Top Players by Opioid-Induced Constipation Price (2021-2026)
  4. 3.4 Global Opioid-Induced Constipation Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Opioid-Induced Constipation Major Company Production Sites & Headquarters
  6. 3.6 Global Opioid-Induced Constipation Company, Product Type & Application
  7. 3.7 Global Opioid-Induced Constipation Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Opioid-Induced Constipation Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Opioid-Induced Constipation Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Opioid-Induced Constipation Tier 1, Tier 2, and Tier 3
4 Opioid-Induced Constipation Regional Status and Outlook
  1. 4.1 Global Opioid-Induced Constipation Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Opioid-Induced Constipation Historic Market Size by Region
  3. 4.2.1 Global Opioid-Induced Constipation Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Opioid-Induced Constipation Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Opioid-Induced Constipation Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Opioid-Induced Constipation Forecasted Market Size by Region
  7. 4.3.1 Global Opioid-Induced Constipation Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Opioid-Induced Constipation Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Opioid-Induced Constipation Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Opioid-Induced Constipation by Application
  1. 5.1 Opioid-Induced Constipation Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Opioid-Induced Constipation Market Size by Application
  6. 5.2.1 Global Opioid-Induced Constipation Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Opioid-Induced Constipation Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Opioid-Induced Constipation Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Opioid-Induced Constipation Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Opioid-Induced Constipation Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Opioid-Induced Constipation Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Opioid-Induced Constipation Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Opioid-Induced Constipation Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Takeda Pharmaceuticals
  2. 6.1.1 Takeda Pharmaceuticals Company Information
  3. 6.1.2 Takeda Pharmaceuticals Business Overview
  4. 6.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolio
  6. 6.1.5 Takeda Pharmaceuticals Recent Developments
  7. 6.2 Bayer
  8. 6.2.1 Bayer Company Information
  9. 6.2.2 Bayer Business Overview
  10. 6.2.3 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Bayer Opioid-Induced Constipation Product Portfolio
  12. 6.2.5 Bayer Recent Developments
  13. 6.3 Sanofi
  14. 6.3.1 Sanofi Company Information
  15. 6.3.2 Sanofi Business Overview
  16. 6.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Sanofi Opioid-Induced Constipation Product Portfolio
  18. 6.3.5 Sanofi Recent Developments
  19. 6.4 Mallinckrodt
  20. 6.4.1 Mallinckrodt Company Information
  21. 6.4.2 Mallinckrodt Business Overview
  22. 6.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Mallinckrodt Opioid-Induced Constipation Product Portfolio
  24. 6.4.5 Mallinckrodt Recent Developments
  25. 6.5 Salix (Bausch Health)
  26. 6.5.1 Salix (Bausch Health) Company Information
  27. 6.5.2 Salix (Bausch Health) Business Overview
  28. 6.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Salix (Bausch Health) Opioid-Induced Constipation Product Portfolio
  30. 6.5.5 Salix (Bausch Health) Recent Developments
  31. 6.6 AstraZeneca
  32. 6.6.1 AstraZeneca Company Information
  33. 6.6.2 AstraZeneca Business Overview
  34. 6.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 AstraZeneca Opioid-Induced Constipation Product Portfolio
  36. 6.6.5 AstraZeneca Recent Developments
  37. 6.7 Progenics Pharmaceuticals
  38. 6.7.1 Progenics Pharmaceuticals Company Information
  39. 6.7.2 Progenics Pharmaceuticals Business Overview
  40. 6.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolio
  42. 6.7.5 Progenics Pharmaceuticals Recent Developments
  43. 6.8 Purdue Pharm
  44. 6.8.1 Purdue Pharm Company Information
  45. 6.8.2 Purdue Pharm Business Overview
  46. 6.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Purdue Pharm Opioid-Induced Constipation Product Portfolio
  48. 6.8.5 Purdue Pharm Recent Developments
  49. 6.9 Nektar Therapeutics
  50. 6.9.1 Nektar Therapeutics Company Information
  51. 6.9.2 Nektar Therapeutics Business Overview
  52. 6.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Nektar Therapeutics Opioid-Induced Constipation Product Portfolio
  54. 6.9.5 Nektar Therapeutics Recent Developments
  55. 6.10 Daiichi Sankyo
  56. 6.10.1 Daiichi Sankyo Company Information
  57. 6.10.2 Daiichi Sankyo Business Overview
  58. 6.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Daiichi Sankyo Opioid-Induced Constipation Product Portfolio
  60. 6.10.5 Daiichi Sankyo Recent Developments
  61. 6.11 Prestige
  62. 6.11.1 Prestige Company Information
  63. 6.11.2 Prestige Business Overview
  64. 6.11.3 Prestige Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Prestige Opioid-Induced Constipation Product Portfolio
  66. 6.11.5 Prestige Recent Developments
  67. 6.12 GSK
  68. 6.12.1 GSK Company Information
  69. 6.12.2 GSK Business Overview
  70. 6.12.3 GSK Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 GSK Opioid-Induced Constipation Product Portfolio
  72. 6.12.5 GSK Recent Developments
  73. 6.13 Shionogi
  74. 6.13.1 Shionogi Company Information
  75. 6.13.2 Shionogi Business Overview
  76. 6.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Shionogi Opioid-Induced Constipation Product Portfolio
  78. 6.13.5 Shionogi Recent Developments
7 North America by Country
  1. 7.1 North America Opioid-Induced Constipation Sales by Country
  2. 7.1.1 North America Opioid-Induced Constipation Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Opioid-Induced Constipation Sales by Country (2021-2026)
  4. 7.1.3 North America Opioid-Induced Constipation Sales Forecast by Country (2027-2032)
  5. 7.2 North America Opioid-Induced Constipation Market Size by Country
  6. 7.2.1 North America Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Opioid-Induced Constipation Market Size by Country (2021-2026)
  8. 7.2.3 North America Opioid-Induced Constipation Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Opioid-Induced Constipation Sales by Country
  2. 8.1.1 Europe Opioid-Induced Constipation Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Opioid-Induced Constipation Sales by Country (2021-2026)
  4. 8.1.3 Europe Opioid-Induced Constipation Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Opioid-Induced Constipation Market Size by Country
  6. 8.2.1 Europe Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Opioid-Induced Constipation Market Size by Country (2021-2026)
  8. 8.2.3 Europe Opioid-Induced Constipation Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Opioid-Induced Constipation Sales by Country
  2. 9.1.1 Asia-Pacific Opioid-Induced Constipation Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Opioid-Induced Constipation Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Opioid-Induced Constipation Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Opioid-Induced Constipation Market Size by Country
  6. 9.2.1 Asia-Pacific Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Opioid-Induced Constipation Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Opioid-Induced Constipation Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Opioid-Induced Constipation Sales by Country
  2. 10.1.1 South America Opioid-Induced Constipation Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Opioid-Induced Constipation Sales by Country (2021-2026)
  4. 10.1.3 South America Opioid-Induced Constipation Sales Forecast by Country (2027-2032)
  5. 10.2 South America Opioid-Induced Constipation Market Size by Country
  6. 10.2.1 South America Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Opioid-Induced Constipation Market Size by Country (2021-2026)
  8. 10.2.3 South America Opioid-Induced Constipation Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Opioid-Induced Constipation Sales by Country
  2. 11.1.1 Middle East and Africa Opioid-Induced Constipation Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Opioid-Induced Constipation Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Opioid-Induced Constipation Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Opioid-Induced Constipation Market Size by Country
  6. 11.2.1 Middle East and Africa Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Opioid-Induced Constipation Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Opioid-Induced Constipation Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Opioid-Induced Constipation Value Chain Analysis
  2. 12.1.1 Opioid-Induced Constipation Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Opioid-Induced Constipation Production Mode & Process
  7. 12.2 Opioid-Induced Constipation Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Opioid-Induced Constipation Distributors
  10. 12.2.3 Opioid-Induced Constipation Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst